Piper Sandler Maintains Overweight on ASLAN Pharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on ASLAN Pharma (NASDAQ:ASLN) with a price target of $15.
March 11, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler reaffirms an Overweight rating on ASLAN Pharma with a $15 price target.
The maintenance of an Overweight rating and a $15 price target by a reputable analyst like Edward Tenthoff suggests a positive outlook on ASLAN Pharma's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90